Viewing Study NCT04965818

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 4:39 AM
Ignite Modification Date: 2026-03-03 @ 12:56 AM
Study NCT ID: NCT04965818
Status: TERMINATED
Last Update Posted: 2024-09-19
First Post: 2021-07-06
Is Gene Therapy: True
Has Adverse Events: False
Brief Title: Phase 1b/2 Study of Futibatinib in Combination With Binimetinib in Patients With Advanced KRAS Mutant Cancer
Sponsor: Taiho Oncology, Inc.
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Advanced or Metastatic Solid Tumors Irrespective of Gene Alterations View
None Non-Small Cell Lung Cancer View
None KRAS Gene Mutation View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Futibatinib View
None Binimetinib View
None MEKi View
None FGFR View
None FGFRi View
None TAS-120 View
None KRASmt View
None NSCLC View